MYOVANT SCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • May 11th, 2021 • Myovant Sciences Ltd. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”) is hereby made between Myovant Sciences, Inc. (the “Company”) and Lauren Merendino (the “Executive”) (collectively, the “Parties”). This Agreement shall become effective on April 5, 2021 (the “Effective Date”).
SEPARATION AGREEMENT AND GENERAL RELEASESeparation Agreement • May 11th, 2021 • Myovant Sciences Ltd. • Pharmaceutical preparations • California
This Separation Agreement and General Release (this “Agreement”) is hereby entered into as of January 3, 2021 by and between Lynn Seely, M.D, an individual (the “Employee”), and Myovant Sciences, Inc. (the “Company”), on behalf of itself, and its direct and indirect parents, subsidiaries and affiliated entities (collectively, the “Company Group”).
DATE] Dear __________,Retention Bonus Agreement • May 11th, 2021 • Myovant Sciences Ltd. • Pharmaceutical preparations
In recognition of your ongoing key contributions and continued importance to the success of Myovant Sciences, Inc. (the “Company”), I am pleased to offer you a special, one-time cash retention bonus, subject the terms and conditions described in this letter (this “Letter Agreement”).
AMENDMENT NO. 2 TO MARKET ACCESS SERVICES AGREEMENTMarket Access Services Agreement • May 11th, 2021 • Myovant Sciences Ltd. • Pharmaceutical preparations
This Amendment No. 2 (this “Amendment”) is entered into as of January 25, 2021 (the “Amendment Effective Date”) by and between Sunovion Pharmaceuticals Inc., a Delaware corporation, having a principle place of business at 84 Waterford Drive, Marlborough, MA 01752 (“Sunovion”) and Myovant Sciences GmbH, a Swiss corporation, having a principle place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Myovant”). Capitalized terms used in this Amendment that are not defined in this Amendment shall have the meaning set forth in the Agreement (as defined below).
COMMERCIAL MANUFACTURING & SUPPLY AGREEMENT BY AND BETWEEN TAKEDA PHARMACEUTICAL COMPANY LIMITED AND MYOVANT SCIENCES GMBH DATE: MAY 30, 2018Commercial Manufacturing & Supply Agreement • May 11th, 2021 • Myovant Sciences Ltd. • Pharmaceutical preparations • New York
This Commercial Manufacturing & Supply Agreement (the “Agreement”) is made effective as of May 30, 2018 (the “Effective Date”) by and between Takeda Pharmaceutical Company Limited, a company having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Takeda”) and Myovant Sciences GmbH, a company having its principal place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Myovant”). Myovant and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
EMPLOYMENT AGREEMENTEmployment Agreement • May 11th, 2021 • Myovant Sciences Ltd. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), is hereby made between Myovant Sciences, Inc. (the “Company”) and David Marek (“you”) (collectively, the “Parties”). This Agreement shall become effective on January 4, 2021 (the “Effective Date”).
